IBDs (inflammatory bowel diseases) are lifelong manifestations that significantly impair the quality of life of those who suffer from them. Although many therapies are now available, including immunomodulatory drugs such as Infliximab which have efficacy in IBD, not all patients respond and some patients generate autoantibodies against these drugs. Hence the search for novel treatments is ongoing. HDACs (histone deacetylases) are responsible for condensation of chromatin in the nucleus of cells and inhibition of gene transcription and are often dysregulated during cancer. HDAC inhibitors allow normal gene transcription to be restored and provide attractive therapeutic options, as they have been shown to be anti-inflammatory and anti-proliferative in cancer. Indeed, two HDAC inhibitors have been recently approved for the treatment of cutaneous T-cell lymphoma in the U.S.A. Recent research using animal models has shown that HDAC inhibitors may have a beneficial effect in colitis by boosting levels of Foxp3+ (forkhead box P3+) T-regulatory cells that dampen inflammation. In the present paper, we outline the background to IBD, HDACs and their inhibitors as well as discussing their current use in models of IBD.
Skip Nav Destination
Article navigation
August 2011
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
July 20 2011
Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases
Alexander J.P. Edwards;
Alexander J.P. Edwards
1
1Mucosal Immunology Group, University of Southampton School of Medicine, Southampton SO16 6YD, U.K.
1To whom correspondence should be addressed (email aje1d10@soton.ac.uk).
Search for other works by this author on:
Sylvia L.F. Pender
Sylvia L.F. Pender
1Mucosal Immunology Group, University of Southampton School of Medicine, Southampton SO16 6YD, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
March 28 2011
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2011 Biochemical Society
2011
Biochem Soc Trans (2011) 39 (4): 1092–1095.
Article history
Received:
March 28 2011
Citation
Alexander J.P. Edwards, Sylvia L.F. Pender; Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases. Biochem Soc Trans 1 August 2011; 39 (4): 1092–1095. doi: https://doi.org/10.1042/BST0391092
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.